KRAS Mutations in NSCLC: Sequencing Across Lines

Dr. Jani opens by noting his interest in KRAS mutations, highlighting that they are more prevalent in elderly populations and that newer treatment approaches and data are rapidly expanding across multiple lines of therapy. He asks Dr. Singhi how KRAS mutation status and subtype influence treatment sequencing.

Dr. Singhi begins by noting that KRAS was traditionally considered undruggable, but that has changed. He explains that KRAS mutations are common, representing about a quarter of non-squamous NSCLC cases. The KRAS G12C subtype is present in approximately 13% of these tumors and already has direct therapeutic implications: FDA-approved inhibitors sotorasib and adagrasib are available for patients with disease progression after first-line treatment. He adds that clinical trials are ongoing to move these targeted therapies into the frontline setting.

Dr. Singhi emphasizes that KRAS disease is not one disease but a family of biologically distinct subtypes. When making frontline treatment decisions outside of a clinical trial, he considers not only the KRAS mutation but also PD-L1 expression, co-mutations, disease burden, patient comorbidities, smoking status, and CNS involvement. The takeaway is that KRAS subtype and clinical context together inform both current post-progression therapy and evolving frontline strategies.

In the next episode, "Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response," the panel explores emerging co-mutations and their impact on prognosis and therapy.